Michèle Barzach
Corporate Officer/Principal bei International AIDS Vaccine Initiative, Inc.
Aktive Positionen von Michèle Barzach
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
International AIDS Vaccine Initiative, Inc.
 International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Corporate Officer/Principal | 30.11.2010 | - |
Karriereverlauf von Michèle Barzach
Ehemalige bekannte Positionen von Michèle Barzach
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| GSK PLC | Direktor/Vorstandsmitglied | 01.01.1997 | 17.05.2004 |
| Independent Dir/Board Member | 01.01.1997 | 17.05.2004 |
Statistik
International
| Vereinigtes Königreich | 2 |
| Vereinigte Staaten | 2 |
Operativ
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
| Corporate Officer/Principal | 1 |
Sektoral
| Health Technology | 3 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| GSK PLC | Health Technology |
| Private Unternehmen | 1 |
|---|---|
International AIDS Vaccine Initiative, Inc.
International AIDS Vaccine Initiative, Inc. Pharmaceuticals: MajorHealth Technology International AIDS Vaccine Initiative, Inc. researches and develops to prevent HIV infection and AIDS. It researches and develops vaccine candidates, conducts policy analyses, and serves as an advocate for the field with offices in Africa, India, and Europe. The firm's HIV research and development focuses on three strategies: the design of vaccine immunogens capable of inducing specialized proteins known as broadly neutralizing antibodies, the optimization and development of these antibodies as prevention products, and the development of replicating viral vectors and mRNA. The company was founded in 1996 by Seth Berkley and Lee C. Smith and is headquartered in New York, NY. | Health Technology |
- Börse
- Insiders
- Michèle Barzach
- Erfahrung